Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators February 7, 2024Kalyn DabbsPress Releases Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting Read More
Genprex to Present at Upcoming BIO CEO & Investor Conference February 6, 2024Kalyn DabbsPress Releases Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes Read More
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer February 5, 2024Kalyn DabbsAcclaim 2Press Releases Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Read More